ARC-7 : A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Lung<br/>CancersCancer LocationLung
Cancers

Systemic therapy,Treatment | LungLung,Non-Small Cell Lung Cancer

Trial Overview Read MoreRead more

This phase II trial is evaluating the safety and effectiveness of a new immunotherapy (zimberelimab) alone and in combination with other types of immunotherapy in patients with advanced non-small cell lung cancer.
 

This trial is treating patients with non-small cell lung cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer

Commercial Sponsor

Arcus Biosciences, Inc.

Summary

Eligible patients will be randomised to 1 of 3 treatment arms: (1) zimberelimab, (2) zimberelimab + AB154 (anti-TIGIT antibody), or (3) zimberelimab + AB154 + AB928 (dual adenosine receptor antagonist). Patients that progress onzimberelimab monotherapy (treatment arm 1) may cross-over to receive combination of zimberelimab + AB154 + AB928 (in treatment arm 3).

Recruiting Hospitals Read MoreRead more

Border Medical Oncology
Albury
Ms Nyree Sarakis
Nsarkis@bordermedonc.com.au
02 6064 1493

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next